New Targeted Therapies for Thyroid Cancer

Author(s): Alessandro Antonelli , Poupak Fallahi , Silvia M. Ferrari , Ilaria Ruffilli , Francesca Santini , Michele Minuto , David Galleri , Paolo Miccoli .

Journal Name: Current Genomics

Volume 12 , Issue 8 , 2011

Become EABM
Become Reviewer

Abstract:

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

Keywords: Anaplastic thyroid cancer, targeted molecular therapies, tyrosine kinase inhibitors, aurora kinase inhibitors, RET, BRAF, VEGFR, V600E, TKIs, peroxisome proliferator-activated receptor-, &, γ

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 8
Year: 2011
Page: [626 - 631]
Pages: 6
DOI: 10.2174/138920211798120808
Price: $58

Article Metrics

PDF: 3